| Identification | Back Directory | [Name]
L-Phenylalanine, N-[6-(3,4-dibromo-2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl- | [CAS]
1810001-93-4 | [Synonyms]
DBM-MMAF
L-Phenylalanine, N-[6-(3,4-dibromo-2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl- | [Molecular Formula]
C49H74Br2N6O11 | [MOL File]
1810001-93-4.mol | [Molecular Weight]
1082.97 |
| Chemical Properties | Back Directory | [Boiling point ]
1069.6±65.0 °C(Predicted) | [density ]
1.325±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.56±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Biological Activity]
DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC)[1]. | [References]
[1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. |
|
|